Ä«Å×°í¸® category
|
|
»ý¸í °øÇÐ, ¾à¹° °³¹ß ¹× ¾à¹° Àü´Þ ½Ã½ºÅÛÀÇ ³ª³ë ÀÔÀÚ |
Nanoparticles in Biotechnology, Drug Development and Drug Delivery Systems |
°³¿ä ¸ñÂ÷ |
Report Scope:
The scope of the report includes an overview of the global market for nanoparticles in biotechnology, drug development and drug delivery, and analyses of global market trends, using 2019 as the base year and forecasting 2020 through 2025 with compound annual growth rate (CAGR) projections.
The report includes analysis of leading and emerging drug products for each nanoparticle type. Profiles of manufacturers of leading products and their specific products are provided. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving nanoparticle-associated drugs.
Market figures are based on revenues at the manufacturer level and are projected in 2019 dollar value. Inflation is not computed into the projection figures. Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products, and other factors affecting the market included in this report are forecasts by product, product category and by company.
The study is arranged to offer an overview of existing nanoparticle technology and of drug markets; it is accompanied by nanoproduct, company, geography, and mechanism of action, with forecasts broken down and covered by geographic region or country.
Patent and clinical trial information is reviewed for various candidate nanodrugs. The status of approvals of drugs in each segment by the FDA and regulatory agencies in other countries is reviewed.
Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change. Revenue figures do not account for variation in local currencies. All market share data presented is on a global basis unless specifically noted.
Regional analysis includes North America (U.S., Canada, Mexico), Europe (U.K., Germany, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the world (South America, and the Middle East and Africa).
Report Includes:
- 43 tables
- An overview of the global nanoparticles in biotechnology, drug development and drug delivery market
- Estimation of the market size and analyses of market trends, with data from 2019, estimates for 2020 and projection of CAGR through 2025
- Highlights of the drug development, formulation, and the development of new drug delivery systems and detailed product analyses within health and wellness subsegments
- Information on nanomedicine and biomedical nanoparticle products and coverage of the next generation vaccines
- Evaluation of current market trends, market size, market forecast, and detailed analysis of drivers, challenges, and opportunities affecting market growth
- Discussion on the role of nanotechnology in COVID-19 vaccine production, components, and methods in the vaccine design for COVID-19 and challenges for vaccine disruptions
- Assessment of various approaches for the treatment of COVID-19, and detailed description of structure and penetration of corona virus
- Details of clinical trials of nanoparticle drugs and drug delivery systems
- A look at the patents, licensing, mergers and acquisitions and market share analysis of the key companies of the industry
- Company profiles of major players including Bristol-Myers Squibb Co., GlaxoSmithKline PLC, Hofmann-La Roche Inc., Merck & Co., and Novartis AG
Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Market Estimate
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Market Overview
Introduction to Nanoparticles
Liposomes
Quantum Dots
Dendrimers
Macromolecule Nanoparticles
Brief History of Nanoparticles
Nanoparticles in Biotechnology
Nanoparticles in Drug Development
Nanoparticles in Drug Delivery Systems
Nanoparticles in Diagnostic Imaging
Major Players in Nanoparticle Drug Delivery Field
Major Nanoparticle/Nanocrystal Drug Revenues
Chapter 4 Market Breakdown by Product Type
Nanoparticles in Biotechnology
Nanoparticles in Drug Development
Nanoparticles in Drug Delivery Systems
Nanoparticles in Diagnostic Imaging
Distribution of Nanobiotechnology and Nanomedicine Companies
Chapter 5 Structure of Nanoparticles
Adoption of Nanoparticles in Applied Markets
Liquid Crystals
Liquid Carriers
Liposomes
Dendrimers
Chitosan and Alginate
Nanocrystals
Quantum Dots
Application of Nanoparticles to Drugs Delivered
Chapter 6 Production of Nanoparticles
Methods of Nanoparticle Formation
Self-Assembly Production
Methods of Stabilization
Methods of Drug Introduction
Polymeric Nanoparticles
Micelles
Liposomes
Gold and Silicon Nanoparticles
Dendrimers
Methods for Loading Biological Molecules into Nanoparticles
Nanocrystal Drugs
Problems with Large-Scale Nanoparticles Production
Chapter 7 Nanoparticles in Biotechnology
Research and Development
Stem Cell Research
Cellular Repair
Paramagnetic and Superparamagnetic Nanoparticles
Biosensors and Quantum Dots
Nanoparticle Research Collaborative Programs
Chapter 8 Nanoparticles in Drug Development and Formulation
Bio Separations
Rapid Drug Analysis
Removal of Impurities and Toxins
Using Nanoparticles to Incorporate Insoluble Drugs
Gold and Silver Nanoparticles in Biomedicine
DNA Nanoparticle Development of DNA-Specific Drugs
Chapter 9 Nanoparticles in Drug Delivery Systems
Nanoparticles in Drug Delivery Applications
Designing a Nanoparticle Drug Delivery System
Nanoparticle Drug Stability
Size Homogeneity of Nanoparticle Preparations
Drug Loading of Nanoparticles
Drug Release from Nanoparticles
External Triggers for Releasing Drugs from Nanoparticles
Binding/Incorporation of Biomolecules to Nanoparticles
Nanoparticle Toxicity
Large Scale Manufacturing
Methods of Administration of Nanoparticle Drugs
Oral Administration
Injection Administration
Transdermal Patch
Implantation Administration
Inhalation Administration
Nanoparticles Suitable for Drug Delivery Systems
Lipid-Based Nanoparticles
Micelle Nanoparticles
Dendrimer Nanoparticles
Polymeric Nanoparticles
Metal-Based Nanoparticles
Biological Macromolecule Nanoparticles
Nanocrystals
Nanoparticle Drug Delivery Systems Now Available
Antibiotic Nanoparticles
Anti-Tumor and Small Molecule Delivery by Nanoparticle
Release of Anti-Cancer Drugs from Nanoparticles
Biomacromolecules Delivered by Nanoparticles
Nanoparticles Coating for Drug Delivery Systems
Removal of Nanoparticles from the body
Chapter 10 In Vitro and In Vivo Diagnostic Imaging
In Vitro Imaging
Nanoparticles in Diagnostic Imaging
Chapter 11 Biomedical Nanoparticle Products
Nanoparticle Drug Delivery Systems and Products
Major Players in Nanoparticle Drug Delivery Systems
Company Pipelines for Nanoparticle Drug Delivery
Drivers of Nanoparticle Products and Marketing
Limiters of Nanoparticle Product Development and Marketing
Chapter 12 Market Breakdown by Region
Market Overview and Discussion
North America
Europe
Asia-Pacific
Rest of the World
South America
Middle East and Africa
Chapter 13 Role of Nanotechnology in COVID-19 Vaccine Production
Introduction
Novel Coronavirus Relying on Various Approaches
Structure of COVID-19 and Penetration
Challenges for COVID-19 Vaccines
Components and Methods in the Design of Vaccines
Antigen
Adjuvant
Nanoparticle/Nanocarrier
Device
Next Generation Vaccines Enabled Through Advances in Nanotechnology
Conclusion on Nanotechnology Usage Against COVID-19
Chapter 14 Patents, Licensing, Mergers and Acquisitions
Recent Licensed, Mergers and Acquisition
Recent Licensing Activity, Mergers and Acquisition
Recent Deals
Nanoparticle Patents
Chapter 15 Company Profiles
BRISTOL-MYERS SQUIBB CO.
CAMURUS AB
CERAMISPHERE PTY LTD.
CYTIMMUNE SCIENCES
GLAXOSMITHKLINE PLC.
HOFFMANN-LA ROCHE INC.
MERCK & CO. INC.
NANOCARRIER CO. LTD.
NOVARTIS AG
|
°ü·Ã¸®Æ÷Æ® |
|
±âºÐ Àå¾ÖÀÇ ÀÓ»ó ½ÃÇè µðÀÚÀÎ °úÁ¦ |
Clinical Trial Design Challenges in Mood Disorders |
¹ßÇà»ç |
Elsevier |
¹ßÇàÀÏ |
23/01/2015 |
°¡°Ý |
-> 93,688¿ø $5,500 |
üÁ¦ |
192 Pages, 9780124051706 |
|
»ýüÀÎ½Ä »ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
110ÂÊ |
|
¹Ì·¡ÀÚµ¿Â÷ »ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
110ÂÊ |
|
°Ç°±â´É½Äǰ »ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
110ÂÊ |
|
ÀΰøÁö´É »ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
95ÂÊ |
|
KÆÐ¼Ç, ÀÇ·ù»ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
110ÂÊ |
|
ÇÉÅ×Å© »ê¾÷ºÐ¾ß Ãë¾÷°¡À̵å |
|
¹ßÇà»ç |
¹Ì·¡±â¼úÁ¤º¸¸®¼Ä¡ |
¹ßÇàÀÏ |
2021-02-15 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
82ÂÊ |
|
ICT ±â¹Ý ½º¸¶Æ® Àç³¾ÈÀü»ê¾÷ ±â¼ú°³¹ß µ¿Çâ°ú ½ÃÀå Àü¸Á |
|
¹ßÇà»ç |
À̽´Äù½ºÆ® |
¹ßÇàÀÏ |
2021-02-04 |
°¡°Ý |
£Ü5,500 |
üÁ¦ |
650ÂÊ |
|
¼ö¼Ò ¹ß»ý ½ÃÀå - ¿ëµµ (¼®À¯ Á¤Á¦¼Ò, ¾Ï¸ð´Ï¾Æ ¹× ¸Þź¿Ã »ý»ê, ¿î¼Û, ¹ßÀü), »ý¼º ¹× Á¦°ø ¸ðµå (ĸƼºê, ÆÇ¸ÅÀÚ), ¿øÃµ (ÆÄ¶õ»ö, ³ì»ö ¹× ȸ»ö ¼ö¼Ò), ±â¼ú ¹× Áö¿ª Àü¸Á ~ 2025³â |
Hydrogen Generation Market by Application (Petroleum Refinery, Ammonia & Methanol production, Transportation, Power Generation), Generation & Delivery Mode (Captive, Merchant), Source (Blue, Green & Grey Hydrogen), Technology, and Region-Forecast to 2025 |
¹ßÇà»ç |
MarketsandMarkets |
¹ßÇàÀÏ |
2021-02 |
°¡°Ý |
$5,500 -> 8,937,500¿ø |
üÁ¦ |
EP 2781, 263 Pages |
|
Áõ° Çö½Ç ½ÃÀå Å©±â, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ - ºÎǰ, µð½ºÇ÷¹ÀÌ (HMD ¹× ½º¸¶Æ® ±Û·¡½º, HUD, ÇÚµå Çïµå ÀåÄ¡), ¾ÖÇø®ÄÉÀ̼Ç, Áö¿ª, ¼¼±×¸ÕÆ®º° Àü¸Á, 2021-2028 |
Augmented Reality Market Size, Share & Trends Analysis Report By Component, By Display (HMD & Smart Glass, HUD, Handheld Devices), By Application, By Region, And Segment Forecasts, 2021 - 2028 |
¹ßÇà»ç |
Grand View Research |
¹ßÇàÀÏ |
2021-02 |
°¡°Ý |
-> 6,187,500¿ø $5,500 |
üÁ¦ |
Number of Pages: 100 , Report ID: 978-1-68038-820-6 |
|
|